MedTrace Logo

A Novel Regimen for Treatment and Prevention of Post-Inflammatory Hyperpigmentation in Skin of Color

NCT06938815 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-11-24

No results posted yet for this study

Summary

This is a single-center, prospective, non-blinded, non-randomized 12 week clinical study to evaluate the efficacy of a SkinCeuticals comprehensive skin care regimen in the reduction of post inflammatory hyperpigmentation (PIH) in skin of color patients. The comprehensive regimen features the Pigment Balancing Peel which combines glycolic acid, lactic acid, kojic acid, vitamin C, and emblica into a treatment that may improve skin discoloration. Participants will supplement the Pigment Balancing Peel with a 11 week regimen that includes the Hydrating B5 Gel, Discoloration Defense, LHA Cleansing Gel, and Brightening UV Defense sunscreen.

Conditions

  • Post Inflammatory Hyperpigmentation

Interventions

OTHER

Hydrating B5 Gel

Vitamin B5 serum with hyaluronic acid

OTHER

Daily Brightening Sunscreen

daily moisturizing sunscreen SPF 30

OTHER

Pigment Balancing Peel

Chemical Peel

OTHER

Discoloration Defense Serum

Dark spot correcting serum

OTHER

LHA Cleansing Gel

exfoliating gel facial cleanser

Sponsors & Collaborators

  • L'Oreal

    collaborator INDUSTRY

  • Narrows Institute for Biomedical Research

    lead OTHER

Principal Investigators

  • Jared Jagdeo, MD MS · SUNY Downstate Health Sciences University Department of Dermatology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-28
Primary Completion
2025-07-01
Completion
2025-07-20

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06938815 on ClinicalTrials.gov